Achieving chronic hepatitis B functional cure: Factors and potential mechanisms
Chronic hepatitis B (CHB) is a significant global health issue affecting approximately 254 million individuals worldwide. Achieving the loss of hepatitis B surface antigen (HBsAg), either with or without seroconversion to hepatitis B surface antibody (HBsAb), is regarded as a functional cure and the...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Virus Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0168170224002004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553873455546368 |
|---|---|
| author | Jiarui Zheng Zilong Wang Linxiang Huang Zixuan Qiu Yandi Xie Suzhen Jiang Bo Feng |
| author_facet | Jiarui Zheng Zilong Wang Linxiang Huang Zixuan Qiu Yandi Xie Suzhen Jiang Bo Feng |
| author_sort | Jiarui Zheng |
| collection | DOAJ |
| description | Chronic hepatitis B (CHB) is a significant global health issue affecting approximately 254 million individuals worldwide. Achieving the loss of hepatitis B surface antigen (HBsAg), either with or without seroconversion to hepatitis B surface antibody (HBsAb), is regarded as a functional cure and the optimal goal for addressing CHB, and can be achieved through various approaches, including induction with nucleos(t)ide analogues (NAs), induction with pegylated interferon alpha (PegIFNα), and spontaneous clearance of HBsAg. Spontaneous clearance of HBsAg is rare, while NAs can directly inhibit HBV DNA, they are unable to act on covalently closed circular DNA (cccDNA), hence inhibiting HBsAg production or clearing HBsAg is extremely challenging. On the other hand, functional cure based on PegIFNα shows good long-term durability, but over 10 % of patients still experience relapse, mostly within 48 weeks after functional cure. Factors related to CHB functional cure with antiviral therapy are complex, including host factors, viral factors, environmental factors, etc. The integration of HBV DNA into liver cells, persistence of HBV cccDNA, insufficient B cell responses and compromised T cell function pose significant barriers to HBV clearance. Therefore, this study systematically reviewed the relevant factors and potential mechanisms influencing functional cure CHB, which can provide a basis for personalized treatment, help predict treatment outcomes and assess prognosis, and provide theoretical support for the advancement of novel treatment strategies and medications. |
| format | Article |
| id | doaj-art-283d19d07d72499ca5b8b0bf2040be27 |
| institution | Kabale University |
| issn | 1872-7492 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Virus Research |
| spelling | doaj-art-283d19d07d72499ca5b8b0bf2040be272025-01-09T06:12:14ZengElsevierVirus Research1872-74922025-01-01351199507Achieving chronic hepatitis B functional cure: Factors and potential mechanismsJiarui Zheng0Zilong Wang1Linxiang Huang2Zixuan Qiu3Yandi Xie4Suzhen Jiang5Bo Feng6Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, ChinaBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, ChinaBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, ChinaBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, ChinaBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, ChinaBeijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, ChinaCorresponding author.; Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Peking University Hepatology Institute, Beijing, ChinaChronic hepatitis B (CHB) is a significant global health issue affecting approximately 254 million individuals worldwide. Achieving the loss of hepatitis B surface antigen (HBsAg), either with or without seroconversion to hepatitis B surface antibody (HBsAb), is regarded as a functional cure and the optimal goal for addressing CHB, and can be achieved through various approaches, including induction with nucleos(t)ide analogues (NAs), induction with pegylated interferon alpha (PegIFNα), and spontaneous clearance of HBsAg. Spontaneous clearance of HBsAg is rare, while NAs can directly inhibit HBV DNA, they are unable to act on covalently closed circular DNA (cccDNA), hence inhibiting HBsAg production or clearing HBsAg is extremely challenging. On the other hand, functional cure based on PegIFNα shows good long-term durability, but over 10 % of patients still experience relapse, mostly within 48 weeks after functional cure. Factors related to CHB functional cure with antiviral therapy are complex, including host factors, viral factors, environmental factors, etc. The integration of HBV DNA into liver cells, persistence of HBV cccDNA, insufficient B cell responses and compromised T cell function pose significant barriers to HBV clearance. Therefore, this study systematically reviewed the relevant factors and potential mechanisms influencing functional cure CHB, which can provide a basis for personalized treatment, help predict treatment outcomes and assess prognosis, and provide theoretical support for the advancement of novel treatment strategies and medications.http://www.sciencedirect.com/science/article/pii/S0168170224002004CHBFunctional cureNAsPegIFNαMechanism |
| spellingShingle | Jiarui Zheng Zilong Wang Linxiang Huang Zixuan Qiu Yandi Xie Suzhen Jiang Bo Feng Achieving chronic hepatitis B functional cure: Factors and potential mechanisms Virus Research CHB Functional cure NAs PegIFNα Mechanism |
| title | Achieving chronic hepatitis B functional cure: Factors and potential mechanisms |
| title_full | Achieving chronic hepatitis B functional cure: Factors and potential mechanisms |
| title_fullStr | Achieving chronic hepatitis B functional cure: Factors and potential mechanisms |
| title_full_unstemmed | Achieving chronic hepatitis B functional cure: Factors and potential mechanisms |
| title_short | Achieving chronic hepatitis B functional cure: Factors and potential mechanisms |
| title_sort | achieving chronic hepatitis b functional cure factors and potential mechanisms |
| topic | CHB Functional cure NAs PegIFNα Mechanism |
| url | http://www.sciencedirect.com/science/article/pii/S0168170224002004 |
| work_keys_str_mv | AT jiaruizheng achievingchronichepatitisbfunctionalcurefactorsandpotentialmechanisms AT zilongwang achievingchronichepatitisbfunctionalcurefactorsandpotentialmechanisms AT linxianghuang achievingchronichepatitisbfunctionalcurefactorsandpotentialmechanisms AT zixuanqiu achievingchronichepatitisbfunctionalcurefactorsandpotentialmechanisms AT yandixie achievingchronichepatitisbfunctionalcurefactorsandpotentialmechanisms AT suzhenjiang achievingchronichepatitisbfunctionalcurefactorsandpotentialmechanisms AT bofeng achievingchronichepatitisbfunctionalcurefactorsandpotentialmechanisms |